Breaking News

Lilly announced on November 23 that solanezumab missed the primary endpoint in the EXPEDITION-3 trial. Lilly will not seek marketing approval for solanezumab to treat mild AD. Earlier-stage trials are continuing.

This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at


Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.


Recent Comments

  1. Kristina Capiak on Anavex 2-73

Further Reading


  1. Probe Shines a Light on γ-Secretase Inhibitor’s Broad Reach
  2. Antibodies Co-Opt Anti-Microbial Response to Clear Intraneuronal Tau
  3. In Parkinson’s, Syncopated DBS May Beat the Current Standard
  4. Emerging Alzheimer’s Therapies Test the Waters at CTAD


  1. Suzanne Hendrix on Constructing Composites for Trials in Early Alzheimer’s
  2. Computational Modeling—Will it Rescue AD Clinical Trials?
  3. Resolving Controversies on the Path to AD Therapeutics
  4. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD

Other Resources

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources